Clinical Trial Detail

NCT ID NCT01266070
Title TKI 258 in Von Hippel-Lindau Syndrome (VHL)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

pheochromocytoma

hemangioblastoma

Therapies

Dovitinib

Age Groups: adult senior

No variant requirements are available.